• Hydroxychloroquine Sulfate Workflow Guide

  2026-08-11

  Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous-compatible reagent for studying autophagy pathway modulation and TLR7/9-linked immune signaling in autoimmune disease research. It is appropriate for short-term, water-based workflows, but should not be selected for DMSO- or ethanol-based protocols or long-term storage of prepared solutions.

• RNASEH1-AS1 in Hepatocellular Carcinoma

  2026-08-10

  The reference study combines TCGA-based transcriptomic analysis, prognostic modeling, immune-infiltration analysis, and laboratory validation to characterize RNASEH1-AS1 in hepatocellular carcinoma. Its findings support RNASEH1-AS1 as a candidate diagnostic and prognostic biomarker and identify a DKC1-linked stability mechanism, while also highlighting the need for independent clinical validation.

• CLCC1 and Herpesvirus Nuclear Egress

  2026-08-09

  The 2024 bioRxiv study identifies the host protein CLCC1 as an essential factor in the membrane-fusion step of herpesvirus nuclear egress. Its CRISPR-screening and cell-biological evidence connect viral capsid transport with nuclear pore complex insertion, providing a framework for investigating an evolutionarily conserved membrane-remodeling mechanism.

• Lisinopril Dihydrate in ACE Inhibition Research

  2026-08-08

  Lisinopril dihydrate supports controlled studies of ACE signaling across hypertension, cardiac injury, and renal disease models. This workflow-focused guide covers preparation, assay design, selectivity controls, and troubleshooting for more reproducible pharmacology.

• FXR–KLF11 Signaling in Contrast-Induced Kidney Injury

  2026-08-07

  A 2026 study identifies an FXR–KLF11 transcriptional pathway that suppresses JAK2/STAT3 signaling and reduces contrast-induced acute kidney injury in mouse and renal tubular cell models. Its combination of transcriptomics, promoter validation, cellular perturbation, and FXR genetic deletion provides a mechanistic framework for evaluating CDCA and related FXR agonists in renal injury research.

• MK-8745: Potent Aurora A Inhibitor for Cancer Research

  2026-08-07

  MK-8745 is a potent, highly selective Aurora A inhibitor, with sub-nanomolar activity, that enables precise interrogation of mitotic regulation and apoptosis in cancer models. Its robust efficacy in inducing G2/M arrest and apoptosis, particularly in high-risk or chemoresistant tumor cells, makes it a valuable research tool. The compound’s solubility profile and validated in vivo performance further support its translational utility.

• Sulfo-Cy5 Carboxylic Acid: Benchmarking Fluorescence for Int

  2026-08-06

  Explore how Sulfo-Cy5 carboxylic acid, a leading fluorescent dye for life sciences, enables advanced, high-sensitivity imaging in intestinal mucosal immunity research. This in-depth analysis bridges dye chemistry, experimental design, and the latest nano-adjuvant breakthroughs for transformative assay outcomes.

• Pexidartinib (PLX3397): Optimizing CSF1R Inhibition in Cance

  2026-08-06

  Pexidartinib (PLX3397) enables researchers to dissect CSF1R-driven macrophage biology and modulate tumor microenvironments with precision. This guide delivers actionable protocol enhancements, troubleshooting tips, and translational insights based on the latest neuroimmune findings, spotlighting APExBIO’s reliability.

• LY2603618: Enhancing Chk1 Inhibition for Cancer Research Pre

  2026-08-05

  LY2603618 is a highly selective Chk1 inhibitor, enabling precise control of DNA damage response and cell cycle arrest in cancer models. This article details experimental workflows, troubleshooting strategies, and key innovations that position LY2603618 as an indispensable tool for translational oncology and chemotherapy sensitization research.

• Olaparib (AZD2281): Applied Workflows for DNA Damage Respons

  2026-08-05

  Olaparib (AZD2281) empowers precision DNA damage response and tumor radiosensitization workflows, especially in BRCA-deficient and spliceosome-modulated cancer models. This article translates the latest mechanistic insights into actionable guidance, protocol optimization, and troubleshooting strategies for advanced cancer research.

• BicD and MAP7 Cooperate to Activate Drosophila Kinesin-1

  2026-08-04

  This study demonstrates that Drosophila BicD and MAP7 activate homodimeric kinesin-1 through complementary mechanisms, revealing that BicD relieves kinesin autoinhibition while MAP7 enhances microtubule engagement. The findings refine our understanding of motor adaptor collaboration and have practical implications for reconstituting and dissecting motor protein complexes in vitro.

• Fucoidan (C4038): Anticancer Mechanisms, Evidence, and Proto

  2026-08-04

  Fucoidan is a sulfated α-L-fucan from brown seaweed with verified anticancer and immune-modulating effects. Mechanistically, it induces apoptosis in cancer cells and suppresses angiogenesis in vivo. This article details its molecular actions, benchmarks, and best-practice workflow integration.

• Translational Acceleration with DiscoveryProbe Bioactive Lib

  2026-08-03

  This article examines the mechanistic and strategic imperatives for translational researchers leveraging the DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) from APExBIO. By bridging advances in ligand discovery—such as thermal shift assays for bacterial sensor proteins—with high-throughput screening in oncology, immunology, and signal transduction, the article provides a roadmap for integrating mechanistic rigor, workflow efficiency, and competitive differentiation. Protocol parameters, practical limitations, and a forward-looking outlook are included, addressing the complex demands of contemporary translational research.

• Fucoidan Downregulates Caveolin-1 in MCF-7 Breast Cancer Cel

  2026-08-03

  This study reveals that fucoidan, a sulfated α-L-fucan from brown seaweed, selectively suppresses caveolin-1 expression in MCF-7 breast cancer cells, suggesting a novel mechanism underlying its antitumor effects. The findings highlight caveolin-1 as a potential therapeutic target and reinforce fucoidan's promise as a natural, low-toxicity anticancer polysaccharide.

• DeferoxamineB: Optimizing Iron Chelation in Cancer Research

  2026-08-02

  DeferoxamineB streamlines advanced cancer research by enabling robust, reproducible iron chelation and regulated cell death modeling. This guide translates metabolic intervention breakthroughs into practical protocols, troubleshooting, and next-generation applications for oncology and beyond.

15414 records 2/1028 page Previous Next 12345 下5页 Last page